FDA Peptide Restrictions: The 2023-2024 Timeline
Peptide Regulation
19 peptides
The number of peptide bulk drug substances the FDA placed on Category 2 of its 503A list between late 2023 and early 2024, restricting them from compounding pharmacies.
FDA Bulk Drug Substances List, 2024
FDA Bulk Drug Substances List, 2024
View as imageBetween late 2023 and early 2024, the FDA placed 19 peptides on Category 2 of its 503A bulk drug substances list, effectively banning compounding pharmacies from preparing them for patients. The action removed legal access to compounds that thousands of clinicians had been prescribing, including BPC-157, thymosin beta-4, CJC-1295, ipamorelin, and thymosin alpha-1, a peptide approved as a pharmaceutical in over 35 countries.[5]
The restrictions triggered legal challenges, physician petitions, and a compounding industry scramble. By September 2024, five peptides had been removed from Category 2. By February 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 restricted peptides would be reclassified to Category 1, restoring legal compounding access. This article traces the full regulatory timeline and explains what changed, what did not, and why it matters for the broader landscape of how the FDA regulates peptides.
Key Takeaways
- The FDA placed 19 peptides on Category 2 of the 503A bulks list in late 2023 through early 2024, citing immunogenicity risks, impurity concerns, and lack of safety data
- Category 2 classification means compounding pharmacies cannot legally prepare these substances, unlike Category 1 which permits compounding under physician prescription
- Five peptides (CJC-1295, ipamorelin, AOD-9604, thymosin alpha-1, selank) were removed from Category 2 in September 2024 after nominators withdrew their submissions
- Thymosin alpha-1's restriction was controversial: it is approved in 35+ countries and has been studied in over 11,000 human subjects (Dominari et al., 2020)
- A study of 153,044 GLP-1 patients found only 8.2% had documented compounded formulation use, versus survey estimates of 23%, suggesting many patients access peptides outside coordinated care (Hendrix et al., 2025)
- On February 27, 2026, HHS Secretary Kennedy announced approximately 14 of 19 restricted peptides would be reclassified to Category 1
What Category 2 Means and Why It Matters
The 503A bulk drug substances list is the FDA's mechanism for regulating which raw ingredients compounding pharmacies may use. Section 503A of the Federal Food, Drug, and Cosmetic Act exempts traditional compounding pharmacies from certain FDA requirements, but only if they use bulk substances that are either components of FDA-approved drugs, appear on the official 503A list, or meet specific safety criteria.
The FDA created a tiered classification system:
- Category 1: Substances that may be used in compounding. Pharmacies can prepare these under physician prescription.
- Category 2: Substances that raise significant safety concerns and may not be used in compounding while under evaluation.
- Category 3: Substances that the FDA has determined should not be used in compounding.
When a peptide is placed in Category 2, it is not technically "banned" in the way a controlled substance is scheduled. It is restricted from compounding, which means the only legal path to patient access is through an FDA-approved drug product. For peptides that have no approved drug product in the US, Category 2 effectively eliminates legal access entirely.
The Full Timeline
Late 2023: The First Restrictions
In October and November 2023, the FDA began updating its interim 503A bulks list, placing multiple peptide bulk drug substances into Category 2. The initial wave included several growth hormone secretagogues, research peptides, and immune modulators. The FDA cited three recurring concerns: risk of immunogenicity (immune reactions to the peptide or its impurities), peptide-related impurities from non-pharmaceutical manufacturing, and limited safety data from controlled human trials.
Early 2024: The List Grows to 19
By early 2024, the full Category 2 peptide list included 19 substances:
- BPC-157 (Body Protection Compound-157)
- Thymosin beta-4 (TB-500)
- CJC-1295 (with and without DAC)
- Ipamorelin
- AOD-9604 (Anti-Obesity Drug fragment)
- GHK-Cu (injectable copper peptide)
- Melanotan II
- MOTS-c (mitochondrial-derived peptide)
- Epithalon/Epitalon
- Kisspeptin-10
- DSIP (Delta Sleep-Inducing Peptide)
- Follistatin 344
- GnRH (Gonadotropin-Releasing Hormone)
- IGF-1 LR3 (Long R3 Insulin-like Growth Factor)
- MGF (Mechano Growth Factor)
- Selank
- Thymosin alpha-1
- Semax
- KPV (Lys-Pro-Val tripeptide)
The restrictions hit the integrative medicine and longevity medicine communities hardest. Clinicians who had been prescribing these peptides through 503A compounding pharmacies, often for years, lost access overnight. Patients on active treatment protocols had their prescriptions terminated.
September 2024: Five Peptides Removed
On September 20, 2024, the FDA announced that five peptides were being removed from Category 2, effective September 27, 2024:
- AOD-9604
- CJC-1295
- Ipamorelin acetate
- Thymosin alpha-1
- Selank acetate (TP-7)
The removal was not based on the FDA reversing its safety assessment. Rather, the original nominators who had submitted these substances for inclusion on the 503A list withdrew their nominations. Without a pending nomination, the FDA removed them from Category 2. The FDA simultaneously announced it would refer several of these peptides to the Pharmacy Compounding Advisory Committee (PCAC) for formal public review.
The thymosin alpha-1 removal drew particular attention. This peptide is manufactured as a pharmaceutical product (thymalfasin) and approved by regulatory agencies in over 35 countries for treating hepatitis B, enhancing vaccine response, and managing immunocompromised states.[5] Mao (2023) reviewed its expanding role in immuno-oncology, noting that it could reduce chemoradiation-induced lymphopenia, potentially enhance checkpoint inhibitor efficacy, and had demonstrated an "exceptional safety profile" across decades of clinical use.[6] Restricting a peptide with this evidence base from US compounding pharmacies while it remained approved abroad struck many physicians as inconsistent.
2025: Legal Challenges and Political Pressure
Throughout 2025, multiple legal challenges were filed against the FDA's Category 2 restrictions. Compounding pharmacy organizations argued that the FDA had exceeded its statutory authority by creating the Category 2 classification, which functioned as a ban without the rulemaking process required by the Administrative Procedure Act.
Simultaneously, the compounded semaglutide controversy brought peptide compounding regulation into public focus. Hendrix et al. (2025) studied 153,044 patients using semaglutide or tirzepatide in a nationwide primary care dataset and found that only 8.2% had documented use of compounded formulations, far below survey estimates suggesting 23% of these patients accessed compounded versions. Users of compounded formulations had longer therapy durations and were more likely to be female, non-Hispanic White, and living in wealthier areas.[3]
Liu et al. (2025) reviewed the compounded semaglutide landscape and identified quality control gaps and fraudulent products in both US and global markets. Their review noted that "compounded semaglutide products currently available to patients may lack the quality controls historically seen with compounded formulations, resulting in risks for dosing errors and adverse health outcomes."[4]
February 2026: The Kennedy Reclassification
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides on the Category 2 list would be reclassified to Category 1, restoring compounding pharmacies' ability to prepare them under physician prescription. The announcement was made on the Joe Rogan Experience podcast before the FDA published a formal updated list.
The peptides expected to return to Category 1 include BPC-157, thymosin alpha-1, TB-500, CJC-1295, ipamorelin, AOD-9604, semax, selank, KPV, MOTS-c, and others. The formal FDA list update was expected within weeks of the announcement.
Category 1 reclassification does not mean these peptides have undergone FDA clinical trials or received drug approval. It means compounding pharmacies can legally prepare them under the 503A framework with a valid physician prescription. The distinction between "legal to compound" and "FDA-approved" remains critical.
The FDA's Stated Rationale
The FDA justified the Category 2 restrictions with three recurring arguments:
Immunogenicity risk. Peptides can trigger immune responses, particularly when they contain impurities from manufacturing. Currier et al. (2008) demonstrated that even commercially synthesized peptides from reputable suppliers contained contaminating peptides at approximately 1% by weight, capable of producing false-positive results in immunological assays.[1] If research-grade peptides from established suppliers carry measurable impurities, the FDA argued that compounded peptides with less standardized quality controls pose higher immunogenicity risks.
Manufacturing impurities. Peptide synthesis generates deletion sequences, truncation products, and racemized amino acids as byproducts. These impurities can affect potency, stability, and safety. For compounding pharmacies sourcing bulk peptide powder from chemical suppliers rather than pharmaceutical manufacturers, the purity specifications may not meet the standards applied to FDA-approved peptide drugs.
Limited human safety data. For many of the 19 restricted peptides, controlled human trial data is sparse or nonexistent. BPC-157, for example, has extensive animal data across hundreds of studies but has never completed a published Phase II or Phase III human trial. The FDA's position was that compounds without established human safety profiles should not be compounded and administered to patients.
The Controversial Cases
BPC-157
BPC-157's restriction was the most publicly debated. This pentadecapeptide derived from human gastric juice has an enormous preclinical literature, with animal studies demonstrating wound healing, tendon repair, gut protection, and neuroprotection across multiple injury models. But the clinical evidence consists primarily of one published human study led by Dr. Edwin Lee, and no large-scale randomized controlled trials have been completed.
The counterargument from prescribing physicians was straightforward: BPC-157 had been prescribed by compounding pharmacies for years with a favorable observed safety profile, and the FDA's own adverse event databases showed minimal serious reports. The FDA countered that absence of reported adverse events in an unmonitored population is not equivalent to demonstrated safety.
Thymosin Alpha-1
Thymosin alpha-1's Category 2 placement was harder to defend on evidentiary grounds. Dominari et al. (2020) reviewed the literature and documented its approval in over 35 countries for hepatitis B treatment and vaccine enhancement, its use in thousands of patients during SARS and COVID-19, and its established safety profile across decades of clinical application.[5] It was one of the first peptides removed from Category 2 in September 2024.
Compounded Semaglutide: The Parallel Story
While not among the 19 restricted peptides (semaglutide is an FDA-approved drug), the compounded semaglutide controversy ran parallel to the peptide restrictions and shaped public perception. The FDA's actions to restrict compounded semaglutide after the drug shortage resolution were seen by some as further evidence of regulatory overreach, and by others as a necessary response to quality concerns documented by Liu et al. (2025).[4]
Habbema et al. (2017) had previously reviewed the risks of unregulated peptide use, focusing on alpha-MSH analogues. They identified problems with preparation, administration, and dosing of substances purchased outside regulated channels, and documented case reports of melanocytic changes, dysplastic nevi, and melanoma in users of unregulated melanotan products.[2] Their findings illustrated the legitimate safety concerns that underpin regulatory action, even when the specific Category 2 mechanism was controversial.
What Changed and What Did Not
The 2026 reclassification restores compounding access for most of the 19 restricted peptides, but several realities remain unchanged:
No peptide moved from "restricted" to "approved." Category 1 reclassification permits compounding under physician prescription. It does not constitute FDA drug approval. These peptides still lack the clinical trial data, manufacturing standards, and labeling requirements of approved pharmaceuticals.
Quality varies by pharmacy. Compounding pharmacies operate under different quality frameworks than pharmaceutical manufacturers. 503A pharmacies compound individual prescriptions under state oversight. 503B outsourcing facilities operate under more FDA oversight but are not held to the same standards as NDA holders. The quality control concerns that motivated the original restrictions have not been resolved by reclassification.
Some peptides remain restricted. Approximately 5 of the 19 peptides are expected to remain on Category 2, though the formal list had not been published at the time of this article. IGF-1 LR3 and follistatin 344, compounds with higher theoretical risk profiles, are likely to remain restricted.
The precedent stands. The FDA established that it can place compounded peptides in a restricted category without the standard rulemaking process. Whether future administrations will use Category 2 similarly remains an open question, and the legal challenges to this mechanism may eventually reach the courts regardless of the current reclassification.
For thymosin alpha-1, BPC-157, and other peptides returning to compounding access, the practical question shifts from legality to quality. With compounding restored, the onus falls on prescribing physicians to source from pharmacies with rigorous analytical testing and on patients to understand that "legal to compound" is not the same as "FDA-approved."
The Bottom Line
Between late 2023 and early 2024, the FDA placed 19 peptides on Category 2 of its 503A bulk drug substances list, effectively eliminating legal compounding access. The rationale centered on immunogenicity risks, manufacturing impurities, and limited human safety data. Five peptides were removed from the restricted list in September 2024 after their nominators withdrew. In February 2026, HHS Secretary Kennedy announced that approximately 14 of the 19 would be reclassified to Category 1, restoring compounding access. The reclassification does not constitute drug approval, and the quality control challenges that motivated the original restrictions remain unresolved.